YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Late-breaking results from the Phase 3b ADlong clinical study presented by Almirall at EADV 2026 show treatment outcomes over time with up to five years of lebrikizumab treatment in moderate-to-severe atopic dermatitis: sustained efficacy…
Almirall's scientific programme at EADV 2026 showcases advances in critical skin diseases, including atopic dermatitis, psoriasis and actinic keratosis, through more than 20 abstracts, including a late-breaking abstracts, alongside two exp…
Company Logo The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial ra…
The collaboration will leverage CrystalO's ion channel small-molecule drug discovery platform and Almirall's expertise in skin science to jointly advance an innovative small-molecule program in medical dermatology. CrystalO will conduct ca…
This article first appeared on GuruFocus. Net Sales: EUR603 million, a 7.5% growth year-on-year. Ilumetri Sales: EUR125 million in the first half, marking a 10.5% year-on-year increase. Ebglyss Sales: Approximately EUR85 million in the fir…
Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Net Sales increased by 7.5% YoY to €6…
The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study. Atopic dermatitis affects a significant number…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Recent performance snapshot Almirall (BME:ALM) has drawn attention after a mixed run for the stock,…
[US Food and Drug Administration (FDA)] The U.S. FDA has approved Eli Lilly’s (LLY [https://seekingalpha.com/symbol/LLY]) bid to market its eczema therapy Ebglyss as a single maintenance dose administered every eight weeks, allowing patien…
Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discover…
* Almirall, S.A. press release [https://backend.almirall.com/sites/default/files/2026-05/EN-Financial_Results_Business_Update_Q1-2026-vFinal.pdf] (LBTSF [https://seekingalpha.com/symbol/LBTSF]): Q1 EBITDA of €67.5M. * Net Sales of €291.0M.…
Almirall's European Dermatology business delivered solid growth of 19.3% YoY, reaching €166.3 MM in Q1 2026, driven by strong momentum across key growth drivers. This contributed to overall Net Sales of €291 MM, up 2.2% YoY and reflecting…
Appointment strengthens Vicore's board with nearly four decades of global pharmaceutical leadership as the company advances buloxibutid toward an important late-stage data readout STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 / Vicore Phar…
Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Almirall (BME:ALM) is Back on Watchlists Almirall (BME:ALM) has drawn fresh attention after recent share price move…
The strategic framework agreement deepens the long-standing partnership, leveraging Artificial Intelligence and High-Performance Computing to identify new opportunities of collaboration in the discovery of new therapies for skin diseases.…
In the ADlong Phase 3b study*, 94% of patients achieved meaningful skin improvement (EASI-75) with up to four years of lebrikizumab treatment, reinforcing the sustained response achieved over time in patients with moderate-to-severe atopic…
Almirall advances scientific leadership in medical dermatology with new data across atopic dermatitis, psoriasis, actinic keratosis and acne, reinforcing its commitment to improving patient outcomes. More than 15 posters will be presented…
Skin Academy brings together leading global experts to advance innovation, collaboration and scientific understanding in medical dermatology, with a focus on improving quality of life for people living with skin diseases. This year’s progr…
NIEL, Belgium, Feb. 24, 2026 /PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its key collaborators, Almirall (www.almira…
This article first appeared on GuruFocus. Net Sales: EUR 1,108 million, a 12.4% increase year-on-year. EBITDA: EUR 233 million, up 21% year-on-year. Gross Margin: 64.4% for the year. R&D Investment: 12.5% of net sales. Net Debt-to-EBITDA R…
Investing.com -- Almirall SA’s eczema biologic Ebglyss tripled sales in its second year on the European market and edged past analyst forecasts, the Barcelona-based dermatology specialist said on Monday, as the company’s 2026 profit guidan…
Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sal…
The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as…
Shanghai EpimAb Biotherapeutics Co., Ltd. SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Almirall overview and recent share performance Almirall (BME:ALM) has drawn investor attention after recent trading, with th…
China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline hydrochloride) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. Sarec…
Ipsen Pharma Ipsen Board of Directors Peter GuenterIpsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026.·GlobeNewswire Inc. PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSE…
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a potentially promising therapeutic opti…
Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 additional studies to be initiated in 2026…
Almirall (BME:ALM) shares edged higher today, gaining just under 2%. This move has caught the attention of investors, who are keen to understand what might be driving sentiment for the Spanish pharmaceutical company. See our latest analysi…
This article first appeared on GuruFocus. Net Sales Growth: Nearly 13% year-on-year increase in the first nine months of 2025. Gross Margin: Moderated to 64.9% of sales, reflecting ongoing pressure related to illumetric royalties. EBITDA:…
Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress Sustained strong growth momentum with 12…
Company Logo The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population,…
Recordati NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and will be based in the Group’s headq…
Almirall (BME:ALM) shares have quietly advanced this month, gaining 7% over the past four weeks. Investors might be paying closer attention to the company’s fundamentals as the company shows steady annual revenue and net income growth. See…